Physician profile
Manjit Kaur
NPI 1639724628
$1,314.37
in general payments reported to CMS, 2019-2025
14 companies · $72.90 in 2025
The $72.90 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $396 · 2023: $373 · 2024: $473 · 2025: $72.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.37 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $196.48 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $167.04 | 2022-2025 | Prolia, Evenity, Repatha |
| Abbvie INC. | $103.37 | 2022-2023 | |
| Glaxosmithkline, LLC. | $102.99 | 2023-2024 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.89 | 2022-2024 | Jardiance |
| Dexcom, INC. | $83.07 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $65.32 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $60.20 | 2022-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $50.44 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.14 | 2024-2025 | |
| Exact Sciences Corporation | $35.78 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $30.03 | 2022-2023 | Steglatro, Steglujan, Belsomra |
| Kowa Pharmaceuticals America, INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjit Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.